PROMO!
First order? Get 10% OFF with this code: 1storder
Follistatin 344 is a 344-amino-acid isoform of follistatin, a secreted glycoprotein characterized by three follistatin domains and a heparin-binding region, and studied for its molecular interactions with transforming growth factor-β (TGF-β) superfamily proteins.
The 344-amino-acid precursor form of human follistatin, a secreted glycoprotein produced by the FST gene, is known as follistatin 344 (FST-344). Follistatin is more appropriately categorized as a multidomain protein/glycoprotein because to its size, intricate folding, and extensive disulfide-bonded structure, despite being frequently referred to commercially as a "peptide." Mature follistatin isoforms are produced by post-translational processing of the 344-residue precursor that results from alternative splicing of follistatin mRNA.
When follicle-stimulating hormone regulation was being studied, follistatin was first isolated from ovarian follicular fluid. Follistatin was found to be a high-affinity extracellular binding protein for activins, which belong to the TGF-β superfamily. According to structural studies, follistatin has three cysteine-rich follistatin domains after its N-terminal domain. Its molecular structure and activin-binding capabilities depend on intact disulfide bonds.
Follistatin has been identified in studies involving myostatin/GDF-8 signaling as well as interactions with activin and other TGF-β-family ligands. The way that follistatin envelops activin and blocks the ligand's receptor-binding surfaces has been described structurally.
Within laboratory research, FST-344 and related follistatin constructs are investigated using recombinant protein expression, ligand-binding assays, cell-based signalling systems, immunochemical techniques, chromatography and mass spectrometry. Importantly, FST-344 should be distinguished from the mature FST-315 and FST-288 forms when describing experimental materials or interpreting analytical data.
The FST gene encodes follistatin 344 (FST-344), a precursor version of human follistatin with 344 amino acids. It is more appropriately categorized as a protein/glycoprotein due to its size and structural complexity, even tho it is occasionally sold as a peptide. FST-344 produces the about 315-residue mature follistatin form, also known as FST-315, after the N-terminal signal peptide is removed.
In terms of structure, follistatin has three follistatin domains (FSD1–FSD3) after an N-terminal domain. A compact, well-organized three-dimensional structure is produced by the numerous intramolecular disulfide bonds formed by the abundance of cysteine residues in these domains. Thus, disulfide connection and proper protein folding are crucial features of physiologically intact follistatin.
Follistatin is also glycosylated, meaning its experimentally observed molecular mass can vary according to expression system and glycosylation state rather than corresponding solely to the mass predicted from its amino-acid sequence. This distinguishes FST-344 from simple synthetic linear peptides.
The molecule comprises both hydrophilic and hydrophobic regions, although as a soluble extracellular protein it is generally compatible with appropriately formulated aqueous buffers. Its charge and solubility depend on pH, ionic strength and formulation conditions. Compared with short peptides, FST-344 requires greater attention to conformational stability because heat, extreme pH, chemical denaturants and repeated freeze–thaw cycles can disrupt its tertiary structure, glycosylation-dependent characteristics or disulfide-stabilised domains.
Follistatin 344 (FST-344) has been studied in the lab using follistatin's known extracellular ligand-binding characteristics. Follistatin is not primarily described as activating its own cell-surface receptor, in contrast to traditional peptide agonists. Rather, follistatin is described in published experimental research as an extracellular antagonist and binding protein of specific ligands of the transforming growth factor-beta (TGF-β) superfamily, namely activins.
Activin Binding and Receptor Interference
Follistatin 344 (FST-344) has been studied in the lab using follistatin's known extracellular ligand-binding characteristics. Follistatin is not primarily described as activating its own cell-surface receptor, in contrast to traditional peptide agonists. Rather, follistatin is described in published experimental research as an extracellular antagonist and binding protein of specific ligands of the transforming growth factor-beta (TGF-β) superfamily, namely activins.
TGF-β Superfamily Signaling
Activin receptor signaling normally involves type II receptors such as ACVR2A and ACVR2B, recruitment of type I receptors and subsequent phosphorylation of intracellular SMAD2/3 proteins. Cell-based studies have examined how follistatin–activin complex formation alters access of the ligand to this receptor-mediated signalling system. Follistatin therefore acts principally at the extracellular ligand level rather than through direct inhibition of SMAD proteins.
Myostatin/GDF-8 Interactions
Published experimental studies have also characterised interactions between follistatin and myostatin (GDF-8), another TGF-β superfamily ligand. Binding assays, structural investigations and experimental models have examined follistatin-mediated sequestration of myostatin and interference with its interaction with activin type II receptors.
Isoform-Dependent Molecular Interactions
The differences in follistatin isoforms' interactions with cell-surface heparan sulfate proteoglycans have also been studied. These variations may have an impact on ligand-binding behavior and extracellular localization. Crucially, FST-344 is a precursor construct; mechanistic results for mature follistatin isoforms like FST-315 and FST-288 are frequently documented; hence, these forms should not be regarded as empirically equivalent.
Generally, rather than activating a specific follistatin receptor, follistatin research focuses on extracellular ligand sequestration, activin/myostatin binding, and modulation of TGF-β-superfamily receptor signaling.
This summary reflects findings reported in published preclinical and in vitro research. The original studies supporting this information are listed in the references.
Research involving Follistatin 344 includes investigation of its role as the precursor associated with the FST-315 follistatin isoform. Experimental studies have examined post-translational processing, secretion and the molecular distinctions between FST-344-derived material and other follistatin forms. This is particularly important because FST-344, FST-315 and FST-288 should not be treated as structurally identical experimental materials.
A major area of follistatin research concerns its high-affinity interaction with activins, particularly activin A. Biochemical binding assays and structural techniques have been used to characterise follistatin–activin complexes, binding interfaces and the manner in which follistatin occupies receptor-binding surfaces on activin.
The relationship between follistatin and myostatin (GDF-8), another member of the TGF-β superfamily, has been well studied. The molecular interaction between follistatin and myostatin and its connection to activin type II receptor signaling has been described in experimental models using ligand-binding assays, recombinant proteins, and cell-based systems.
Cell-based research has examined follistatin in experimental systems involving ACVR2A, ACVR2B and downstream SMAD2/3 signaling. Rather than studying FST-344 as a conventional receptor agonist, these experiments investigate how extracellular ligand sequestration modifies the availability of activin-family ligands for receptor-complex formation.
Follistatin isoforms have been investigated for differences in their affinity for heparan sulphate proteoglycans at cell surfaces and within extracellular matrices. Comparative studies of FST-315 and FST-288 are particularly relevant for understanding how structural differences influence extracellular localisation, ligand availability and molecular distribution.
X-ray crystallography and other structural approaches have been used to investigate the interaction between follistatin domains and TGF-β-family ligands. Research focuses on the N-terminal domain and three follistatin domains (FSD1–FSD3), including the contribution of disulfide-stabilised structures to ligand recognition.
Because FST-344 is a complex, disulfide-rich glycoprotein rather than a simple linear peptide, laboratory research also examines recombinant expression, glycosylation, folding and protein integrity. Chromatography, electrophoresis, immunoblotting and mass spectrometry can be employed to distinguish correctly expressed material from aggregates, fragments and other protein species.
Follistatin 344 (FST-344) requires more structural evaluation for analytical verification than is usually required for a short synthesized peptide. Verification should determine protein identity, molecular integrity, and purity while taking post-translational changes and possible processing products into consideration because FST-344 is a 344 amino acid, disulfide-rich glycoprotein precursor.
Peptide mapping after enzymatic digestion provides sequence-level confirmation of the FST-344 construct, while LC-MS or high-resolution mass spectrometry can provide molecular identity information. SDS-PAGE can evaluate apparent molecular mass, fragmentation, aggregation, and disulfide-dependent behavior in both reducing and non-reducing circumstances. Aggregates and higher-molecular-weight species can also be found using analytical chromatography, such as size-exclusion chromatography (SEC).
Follistatin is glycosylated, hence, the glycan profile and recombinant expression system may affect the measured molecular mass. Glycosylation and disulfide-bond analysis offer extra structural confirmation where applicable.
Store Follistatin 344 (FST-344) at 2–8°C in its lyophilized form, as specified on the current batch COA. Keep the vial sealed and store it away from moisture, heat, and direct light.
During handling, keep the material protected from unnecessary temperature changes. Avoid vigorous agitation and repeated freeze thaw cycles, as these conditions may affect protein integrity.
Follistatin 344 is not so much a typical short peptide as it is a protein. It is a 344-amino acid precursor that goes thru post-translational processing and has several structural domains and disulfide linkages. Although it is frequently used in commerce, the term "Follistatin 344 peptide" does not accurately describe its entire structural complexity.
FST-344 refers to the 344-amino-acid precursor associated with the FST315 isoform. Following removal of its N-terminal signal peptide and C-terminal processing, the secreted mature protein contains approximately 315 amino acids. Consequently, FST-344 and FST-315 describe related but structurally distinct stages/forms of follistatin.
FST-344 is the precursor associated with FST315, whereas FST-288 arises from an alternatively spliced FST transcript and lacks the extended acidic C-terminal sequence characteristic of FST315. This structural difference contributes to substantially stronger association of FST-288 with cell-surface heparan sulphate proteoglycans.
Follistatin is best characterised for its high-affinity binding to activins, particularly activin A. Published experimental studies have also characterised interactions with other members of the TGF-β superfamily, including myostatin (GDF-8) and several related ligands. Binding affinity and biological relevance can differ substantially between individual ligands.
Follistatin-derived proteins have demonstrated direct interaction with myostatin/GDF-8 in biochemical and structural studies. Research has examined the formation of follistatin–myostatin complexes and how this association interferes with the availability of myostatin for interaction with its signalling receptors.
Follistatin is not known to signal through a dedicated follistatin receptor. Instead, it principally functions as an extracellular ligand-binding protein, sequestering molecules such as activin and thereby modifying their availability for interaction with cell-surface receptors. Some follistatin isoforms can also associate with cell-surface heparan sulphate proteoglycans.
Structural studies have shown that follistatin can form a high-affinity complex around activin, covering molecular surfaces that activin normally uses to interact with its type I and type II receptors. This ligand-sequestration mechanism prevents normal assembly of the activin receptor complex and consequently interferes with downstream receptor-mediated signalling.
The apparent molecular weight of follistatin can differ from the mass predicted solely from its amino-acid sequence because follistatin is glycosylated and exists in multiple processed isoforms. Recombinant expression system, glycan composition, proteolytic processing and analytical conditions can all influence the molecular species observed by techniques such as SDS-PAGE or mass spectrometry.
Follistatin 344 (FST-344) is provided for research and laboratory use only. It is not for human or animal consumption and is not intended for diagnostic, therapeutic, or clinical applications. Information on this page is provided solely for scientific and technical reference and should not be interpreted as supporting any medical use or clinical application.
